Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP229882.RA_mB1-inWWIUM0P1h0_YrQT49nowc39kGovvBhRvbens130_assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP229882.RA_mB1-inWWIUM0P1h0_YrQT49nowc39kGovvBhRvbens130_provenance.
• NP658123.RAVrNdCV8MGTXB1XqvEr5YgTpndgX-pPuMUMptb9VRBzE130_assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP658123.RAVrNdCV8MGTXB1XqvEr5YgTpndgX-pPuMUMptb9VRBzE130_provenance.
• assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP817308.RAL4am4CDt1RlNz7ZDU6j0W544szSq_QRQ7ENuW_cvy7w130_assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817308.RAL4am4CDt1RlNz7ZDU6j0W544szSq_QRQ7ENuW_cvy7w130_provenance.
• NP658124.RAMAiY2CHYyEv0c1mWTmsFqi0yUl8Qo6Wgit0nlq5cB1s130_assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP658124.RAMAiY2CHYyEv0c1mWTmsFqi0yUl8Qo6Wgit0nlq5cB1s130_provenance.
• NP658125.RAPHQWqr4sGo6rg_23JNcdaZc3COdlaC4DgOmRER8a4Gw130_assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP658125.RAPHQWqr4sGo6rg_23JNcdaZc3COdlaC4DgOmRER8a4Gw130_provenance.
• assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP817228.RAna-TqVBgPqG6orRid1Qyv_T6hdTYarNKyGmBBzLlmRo130_assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817228.RAna-TqVBgPqG6orRid1Qyv_T6hdTYarNKyGmBBzLlmRo130_provenance.
• assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP230316.RAv7hRlZIPPb8A7ORrHH22DDL_ZWrAhGasVe4Xlle-bgg130_assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP230316.RAv7hRlZIPPb8A7ORrHH22DDL_ZWrAhGasVe4Xlle-bgg130_provenance.
• NP658120.RAuoNcP5NfHqEqa-5T6Cj9d5eBnAeFz8vrtsrRS-wcqbc130_assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP658120.RAuoNcP5NfHqEqa-5T6Cj9d5eBnAeFz8vrtsrRS-wcqbc130_provenance.
• NP658121.RAhBsKHiKYIvzmZd7dLy41Pz9M4PC_GhXNPwEL3JDdWeM130_assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP658121.RAhBsKHiKYIvzmZd7dLy41Pz9M4PC_GhXNPwEL3JDdWeM130_provenance.
• NP658122.RAgq2flajLNQgbdSGK96Pod_gi7fvC5W57PfAESFPPrk8130_assertion description "[Development of a biologically active monoclonal antibody (6313/G2) against the AT1 receptor prompted the testing of a recombinant short-chain variable fragment form (R6313/G2) against breast cancer cells in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP658122.RAgq2flajLNQgbdSGK96Pod_gi7fvC5W57PfAESFPPrk8130_provenance.